Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High Dose Lovastatin Clear all
Completed No phase listed Observational

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

NCT00880178
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Simvastatin and Extended-Release niacin, Simvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 13, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 13, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 13, 2026, 5:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

NCT00583102
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Lovastatin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

NCT01976936
View directory record Official record
Conditions
Stroke, Rhabdomyolysis, Jaundice
Interventions
Low Dose Lovastatin, Placebo, High Dose Lovastatin
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 13, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 13, 2026, 5:32 PM EDT
Not listed Phase 4 Interventional

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

NCT00736463
View directory record Official record
Conditions
HDL Cholesterol
Interventions
Simvastatin, Atorvastatin 80 mg
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

NCT00580970
View directory record Official record
Conditions
Prostate Cancer
Interventions
lovastatin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 13, 2026, 5:32 PM EDT
Completed No phase listed Observational

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

NCT01178320
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Simvastatin, simvastatin plus extended-release niacin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3015014 in Participants With High Cholesterol

NCT01890967
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LY3015014, Placebo, Statin, Ezetimibe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Encino, California • Lancaster, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 13, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

NCT01004705
View directory record Official record
Conditions
Elevated LDL Cholesterol
Interventions
Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL

NCT00828282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Simvastatin
Drug
Lead sponsor
John Haslip
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455
View directory record Official record
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 13, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)

NCT00243880
View directory record Official record
Conditions
Stroke
Interventions
lovastatin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 13, 2026, 5:32 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

NCT00963664
View directory record Official record
Conditions
Melanoma, Malignant Melanoma
Interventions
lovastatin, interferon alfa-2b
Drug
Lead sponsor
NeoPlas Innovation
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 13, 2026, 5:32 PM EDT